Article
Modulating vascular intimal hyperplasia using HSV-1 mutant requires activated MEK.
Gene therapy - 1 Feb 2013
Skelly C L, He Q, Spiguel L, McCormick S, Weichselbaum R
Abstract excerpt
Outcomes of cardiovascular procedures, such as angioplasty and stent or bypass grafting are limited by failure, predominantly caused by pathological smooth muscle cell (SMC) proliferation, known as intimal hyperplasia. Local delivery of a genetically engineered herpes simplex virus (HSV) is known to block vascular SMC proliferation while allowing for re-endothelialization. However, the mechanism this mutant virus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
